Clinical trials: Hospital-acquired Pneumonia (HAP)
Pneumonia, Ventilator-Associated, Pneumonia, Hospital Acquired
FilmArray Pneumonia Panel for Antimicrobial Treatment of HAP/VAP in Intensive Care Units
Microbiologic diagnosis of pneumonia is often limited by a long turnaround time of cultures. This randomized trial aims to evaluate the impact of BioFire FilmArray Pneumonia panel on (1) the proportion of appropriate/optimal…
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Hospital Acquired, Critically Ill
- Trial name
- FilmArray (NCT05214716)
- Testing
- FilmArray Pneumonia panel
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Kyungmin Huh
Mechanical Ventilation Pressure High
Mechanical Ventilation Parameters in HAP Patients
Hospital-acquired pneumonia (HAP) in patients in intensive care often requires the mechanical ventilation (MV). Management and weaning from MV are given by specificity of this type of pulmonary inflammation.
- Trial name
- NCT03111303
- Testing
- mechanical ventilation
- Volunteers
- 2,654 people
- Sponsor
- University Hospital Olomouc
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia
VAPERO is a randomized, unblinded, controlled study to measure the impact of a strategy based on the Unyvero® multiplex PCR test on the adjustment of antimicrobial therapy in patients suspected with ventilator-associated or…
- Trial name
- VAPERO (NCT03711331)
- Testing
- FilmArray® Pneumonia panel plus, Standard care
- Where
- France
- Volunteers
- 161 people
- Sponsor
- University Hospital, Lille
Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial
Critically ill people who need a breathing machine often develop hospital-acquired lung infections. These infections are commonly treated with the antibiotics piperacillin/tazobactam or meropenem.
- Conditions
- Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP), Nosocomial Respiratory Infection, Critical Illness
- Trial name
- ROAD-RCT (NCT07820501)
- Testing
- Resistance-Optimised Precision Dosing, Standard Care Dosing
- Volunteers
- 610 people
- Sponsor
- The University of Queensland
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP)
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia…
- Conditions
- Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
- Trial name
- APEKS-NP (NCT03032380)
- Testing
- Cefiderocol, Meropenem, Linezolid
- Where
- 119 sites in United States, Belgium and 17 more
- Volunteers
- 300 people
- Sponsor
- Shionogi
Ventilator-associated Pneumonia, Hospital-acquired Pneumonia
Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit
Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
- Trial name
- NCT04700202
- Testing
- Observational
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Methodist Health System
Nosocomial Pneumonia
International Study on NoSocomial Pneumonia in Intensive CaRE (PneumoINSPIRE)
The International study on NoSocomial Pneumonia in Intensive CaRE (PneumoINSPIRE) is a prospective, international, multicentre, observational, cohort study.
- Trial name
- PneumoINSPIRE (NCT02793141)
- Testing
- No intervention
- Where
- 2 sites in Australia, Greece
- Volunteers
- 1,657 people
- Sponsor
- The University of Queensland
Hospital-acquired Pneumonia, Antibiotic Resistant Infection
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.
- Trial name
- CHAPTER (NCT06028217)
- Testing
- prognosis status
- Volunteers
- 4,000 people
- Sponsor
- Ruijin Hospital
Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired…
- Trial name
- NCT03439124
- Testing
- ceftobiprole medocaril, IV standard-of-care cephalosporin
- Where
- 19 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 138 people
- Sponsor
- Basilea Pharmaceutica
Ventilator-Associated Pneumonia
Epidemiology of Risk Factors for Hospital-acquired Pneumonia (HAP) in Intensive Care Unit (ICU) Patients
A retrospective, observational study compiled data from all consecutively admitted patients older than 18 years at ICU University Hospital in Olomouc in the period from 1 January 2011 to 31 December 2015 who fulfilled the…
- Trial name
- NCT02779933
- Testing
- Epidemiology od HAP
- Volunteers
- 310 people
- Sponsor
- University Hospital Olomouc
HAP - Hospital Acquired Pneumonia, VAP - Ventilator Associated Pneumonia
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
Multicenter, randomized, controlled, open-label trial to assess if semiquantitative multiplex PCR assay, as compared to conventional microbiology, can reduce the percentage of patients without microbiological diagnosis in the…
- Trial name
- LIGHTNING (NCT05952648)
- Testing
- Lower tract respiratory samples, Multiplex PCR assay (Film-array Pneumonia Panel Plus), Lower respiratory tract standard culture
- Where
- 4 sites in Italy
- Volunteers
- 126 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hospital-acquired Pneumonia
"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.
The goal of this clinical trial is to determine the safety (phase II), then efficacy (phase III) of baricitinib plus standard of care (SOC) as compared to SOC alone for the treatment of hospital-acquired pneumonia in patients…
- Trial name
- TREAT-HAP (NCT05914584)
- Testing
- Baricitinib 4 MG
- Where
- 29 sites in Belgium, France and 2 more
- Volunteers
- 450 people
- Sponsor
- Nantes University Hospital
Critically Ill Patients
Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study
PREV-HAP study is part of a larger project entitled 'Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia' (HAP2), funded by the European Union's H2020 research and innovation programme…
- Trial name
- PREV-HAP (NCT04793568)
- Testing
- Recombinant Interferon gamma 1b (IMUKIN®)
- Where
- 18 sites in France, Greece and 1 more
- Volunteers
- 109 people
- Sponsor
- Nantes University Hospital
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Gram-negative Bacterial Infections, Bloodstream Infections (BSI)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are: To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed…
- Conditions
- Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP)
- Trial name
- NCT04335539
- Testing
- Cefiderocol, Standard of Care
- Where
- 23 sites in Belgium, Estonia and 7 more
- Volunteers
- 53 people
- Sponsor
- Shionogi
Pneumonia
Improving Oral Care to Reduce Hospital-Acquired Pneumonia (HAP) in the Acute Neurologically Impaired Adult
Hypothesis: The investigators hypothesize that the current oral protocol is sub-optimal and an enhanced protocol will decrease the incidence of hospital acquired pneumonia (HAP)in the acute, non-intubated, care-dependent…
- Trial name
- NCT01498601
- Testing
- Enhanced oral care protocol
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Fraser Health
Pneumonia, Ventilator-Associated
The DIPOD Study (Diagnosis Improvement of Pneumonia by Organ Dysfunction)
The place of analysis of organ dysfunction in relation to the diagnosis of nosocomial pneumonia in intensive care is not yet defined.
- Trial name
- DIPOD (NCT02683122)
- Where
- France
- Volunteers
- 298 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Hospital Acquired Pneumonia
Early Mobility Bundle to Prevent Hospital Acquired Pneumonia (HAP) in Medical Inpatients
Hospital acquired pneumonia (HAP) is a common complication of extended hospital stay. In surgical specialities and critical care early physiotherapy is a recognised way of preventing such infections, and reducing length of…
- Trial name
- NCT01769742
- Testing
- Early mobility bundle
- Where
- United Kingdom
- Volunteers
- 1,178 people
- Sponsor
- University of Birmingham
Hospital Acquired Pneumonia (HAP), Cardiovascular and Respiratory Disease
Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia
The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand the causal links between…
- Trial name
- HOMI-LUNG-HAP (NCT06602934)
- Testing
- Blood samples, Oropharyngeal swabs, ECG
- Where
- 5 sites in France
- Volunteers
- 300 people
- Sponsor
- Nantes University Hospital